Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734135 | 0.86 | ALDH1A1 (0.39) | ALDH1A1TP53TSHRL3MBTL1HPGD | |
| SCHEMBL3136565 | 0.83 | ALDH1A1 (0.44) | ALDH1A1TP53TSHRL3MBTL1HPGD | |
| SCHEMBL6969487 | 0.83 | ALDH1A1 (0.37) | ALDH1A1TP53TSHRL3MBTL1HPGD | |
| SCHEMBL13436162 | 0.81 | CRBN (0.41) | ALDH1A1TP53TSHRL3MBTL1HPGD | |
| SCHEMBL1563693 | 0.81 | CRBN (0.41) | ALDH1A1TP53TSHRL3MBTL1HPGD | |
| SCHEMBL4119686 | 0.76 | L3MBTL1 (0.46) | ALDH1A1TP53TSHRL3MBTL1HPGD | |
| SCHEMBL6234856 | 0.76 | L3MBTL1 (0.32) | ALDH1A1TP53TSHRL3MBTL1 | |
| SCHEMBL6959890 | 0.76 | L3MBTL1 (0.32) | ALDH1A1TP53TSHRL3MBTL1 | |
| SCHEMBL11318749 | 0.76 | ALDH1A1 (0.32) | ALDH1A1TP53TSHRL3MBTL1HPGD | |
| SCHEMBL6959896 | 0.76 | L3MBTL1 (0.37) | ALDH1A1TP53TSHRL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446109-B2 | Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-09-20 | — | — | US | disclosed |
| EP-2369345-B1 | Glycoconjugates and their use as potential vaccines against infection by shigella flexneri | PASTEUR INSTITUT (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-20140161793-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | INSERM (FR) | 2014-06-12 | — | — | US | disclosed |
| US-20130243751-A1 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | 2013-09-19 | — | — | US | disclosed |
| US-8124380-B2 | Oligo/polysaccharides bound to carrier; immunogens; monoclonal antibodies; chimeric antibodies; kits; host cells; transgenic plants/animals | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-02-28 | — | — | US | disclosed |
| EP-2369345-A1 | Glycoconjugates and their use as potential vaccines against infection by shigella flexneri | Institut Pasteur (FR) | 2011-09-28 | — | — | EP | disclosed |
| EP-1642132-B1 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | PASTEUR INSTITUT (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20080112951-A1 | Glycoconjugates and Their Use as Potential Vaccines Against Infection by Shigella Flexneri | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-05-15 | — | — | US | disclosed |
| EP-1642132-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | INSTITUT PASTEUR (FR) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005003775-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | INSTITUT PASTEUR (FR) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243751-A1 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | FUT6, GNE, STT3B | ALDH1A1 3621/4885TP53 3163/4885TSHR 3217/4885 |
| US-20140161793-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | FUT6, GNE, STT3B | ALDH1A1 3621/4885TP53 3163/4885TSHR 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.